News

Oblique Therapeutics has yet again received grants from Vinnova

This year we received funding for 3 different development projects:

• A new class of selective antagonistic TRPV1 for pain therapyA project we continue to get funded for.
  In collaboration with KI.

• Engineering of nano-sized membrane vesicles for intracellular delivery of therapeutic antibodiesDesigning a new technology to get antibodies inside the cell
  A project in collaboration with KTH, KI and SLU

• Improved cancer diagnostic and drug developmentA project in collaboration with RISE among others

Oblique Therapeutics’ platform technology will be presented at the DDIP in Munich

Professor Owe Orwar, CEO of Oblique Therapeutics will make the first public disclosure of the company´s transformative platform for for functional antibody discovery and design at the 3rd Drug Discovery Innovation Programme 5-6 Oct 2017 Munich, Germany.

Watch our CSO presenting the company at Life Science-dagen 2017

Short non-confidential presentation of Oblique Theraputics by Carolina Trkulja, CSO in Swedish with English text.
https://m.youtube.com/watch?v=3naoT9VZYfk

Oblique Therapeutics has received a grant from Vinnova

Oblique Therapeutics has received a grant from the Vinnova future biological medicines program to develop functional antibodies against TRPV1 and TRPV2 for inflammatory/idiopathic pain and metastatic cancer, respectively.

Oblique Therapeutics has entered into a collaboration agreement with Pharma

Oblique Therapeutics has entered into a discovery agreement with a global leader in diabetes medicines and care regarding the development of two functional antibodies against type 2 diabetes targets.